Equities

EBAC

KYG3167F1028

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
12.8 ^USD	-0.93%		+6.49%	+14.39%

2023	European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index	CI
2023	Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.	CI

European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 05:34 pm EDT

European Biotech Acquisition Corp. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net income was USD 0.200685 million compared to USD 0.473524 million a year ago.
For the six months, net income was USD 1.71 million compared to USD 0.728364 million a year ago.

Latest news about EURO BIOT

European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index	23-03-02	CI
Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.	23-03-01	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
European Biotech Acquisition, Oculis Strike Merger Agreement	22-10-17	MT
Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million.	22-10-16	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
European Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Certain Class B Ordinary Shares of European Biotech Acquisition Corp. are subject to a Lock-Up Agreement Ending on 15-SEP-2021.	21-09-14	CI
European Biotech Acquisition Corp.(NasdaqCM:EBAC) added to NASDAQ Composite Index	21-05-19	CI
European Biotech Acquisition Corp. announced that it has received $4.55096 million in funding from Lsp Sponsor Ebac B.V.	21-05-02	CI
European Biotech Acquisition Corp. Appoints Mohammad Sohail Fazeli to the Board	21-03-18	CI
European Biotech Acquisition Corp. has completed an IPO in the amount of $120 million.	21-03-18	CI
European Biotech Acquisition Corp. has filed an IPO in the amount of $100 million.	21-02-17	CI
European Biotech Acquisition Corp. announced that it expects to receive $4 million in funding from Lsp Sponsor Ebac B.V.	21-02-16	CI

Chart EURO BIOT

Duration

Period

More charts

Company Profile

European Biotech Acquisition Corp is a blanc check company based in the Netherlands. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to primarily seek to identify a company within the European life sciences industry. The aim of the Company is investments in therapeutic drug candidates in clinical development across a range of therapeutic areas, including oncology, diabetes, cardiology, central nervous system (CNS) and orphan diseases.

Sector

More about the company

Income Statement Evolution

More financial data